LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
IRVING, Texas, Feb. 06, 2017 -- Reata Pharmaceuticals, Inc. (NASDAQ:RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with serious or life-threatening diseases, announced today that its senior management team will be presenting at the following investor conferences in the first half of 2017:
Canaccord Genuity Rare Disease Conference
- New York – February 7, 2017
Leerink Partners Global Healthcare Conference
- New York – February 15-16, 2017
Cowen & Co. Health Care Conference
- Boston – March 6-8, 2017
Barclays Capital Global Healthcare Conference
- New York – March 14-16, 2017
Deutsche Bank Health Care Conference
- Boston – May 3-4, 2017
Jefferies Global Healthcare Conference
- New York – June 6-9, 2017
About Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in regulating cellular metabolism and inflammation. Our two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target important transcription factors, called Nrf2 and NF-κB, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Contact: Reata Pharmaceuticals, Inc. (972) 865-2219 [email protected] http://news.reatapharma.com Investor Relations: The Trout Group Lee M. Stern, CFA (646) 378-2922 [email protected]
